Close
Israeli startup CytoReason has secured $80 million in funding to scale up its AI disease models and establish a hub in the United States. The company, founded in 2016, develops computational disease models for predictive insights to aid pharma companies and researchers in finding new drug targets for autoimmune diseases. The funding comes from industry giants like NVIDIA, Pfizer, Thermo Fisher, and OurCrowd.
CytoReason plans to expand the application of its models into additional indications, grow its molecular and clinical data, and set up an office in Cambridge, Massachusetts. The aim is to reach more biotech and pharma companies to accelerate asset development across therapeutic areas and benefit more patients globally. The company's CEO, David Harel, emphasizes the importance of data modelling in revolutionizing pharma R&D.
TechCrunch on MSN.com 6month
Fox Business on MSN.com 8month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
Log in
Sign Up
AI Tools - Popular
AI Tools - Categories
GPTs - Categories
AI for Jobs
